Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice

Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice
复制标题

DOI:
10.1016/j.vaccine.2010.12.117
复制
发表时间:
2011-02-17
期刊:
影响因子:
5.5
通讯作者:
Oishi, Kazunori
Oishi, Kazunori
中科院分区:
医学3区
文献类型:
--
作者:
Ezoe, Hirokazu;Akeda, Yukihiro;Oishi, Kazunori

文献摘要

被引文献

相似文献

在流感流行期间,需要有效的肺炎球菌疫苗来预防继发性细菌性肺炎,这是一种危及生命的疾病。我们研究了低剂量的肺炎球菌表面蛋白a (PspA)加多肌苷-多胞酸(聚(I:C))是否可以预防甲型流感病毒感染后小鼠致命的继发性肺炎球菌肺炎。低剂量PspA加poly(I:C)鼻腔给药小鼠气道和血液中PspA特异性IgG水平高于PspA或poly(I:C)鼻腔给药小鼠。pspa特异性IgG的结合增加了细菌表面的C3沉积。PspA + poly(I:C)免疫小鼠继发感染的存活率高于poly(I:C)单独免疫小鼠。肺部和血液中细菌密度的显著降低与继发性肺炎免疫小鼠的存活率增加有关。PspA + poly(I:C)免疫小鼠血清被动转移可提高继发性肺炎感染小鼠的存活率。我们的数据表明,鼻内PspA疫苗对流感后继发性肺炎具有良好的保护作用,PspA特异性IgG在这种保护中起关键作用。(C) 2010 Elsevier Ltd.版权所有。
Effective pneumococcal vaccines are required for preventing secondary bacterial pneumonia, a life-threatening condition, during epidemics of influenza. We examined whether nasal administration of a low dose of pneumococcal surface protein A (PspA) plus polyinosinic-polycytidylic acid (poly(I:C)) could protect against a fatal secondary pneumococcal pneumonia after influenza A virus infection in mice. PspA-specific IgG but not IgA level was higher in the airways and blood of mice nasally administered a low dose of PspA plus poly(I:C) than in mice nasally administered PspA alone or poly(I:C) alone. Binding of PspA-specific IgG increased C3 deposition on the bacterial surface. The survival rate during secondary infection was higher in mice immunized with PspA plus poly(I:C) than in mice immunized with poly(I:C) alone. The significant reduction in bacterial density in the lung and blood was associated with increased survival of immunized mice with secondary pneumonia. Passive transfer of sera from mice immunized with PspA plus poly(I:C) increased the survival of mice infected with secondary pneumonia. Our data suggest that an intranasal PspA vaccine has promising protective effects against secondary pneumonia after influenza and that PspA-specific IgG plays a critical role in this protection. (C) 2010 Elsevier Ltd. All rights reserved.